{"domain":"artivabio.com","status":"valid","tier":"listed","authority":47,"verified":false,"title":"Artiva Biotherapeutics: Bringing Deep B\\-Cell Depletion to Autoimmune Disease","summary":"Artiva is developing AlloNK®, an investigational, off\\-the\\-shelf NK cell therapy for deep B\\-cell depletion in autoimmune disease, initiating Phase 3 in RA\\.","country":"US","country_source":"ip","publisher_country":null,"publisher_country_source":null,"hosting_country":"US","llms_txt":"https://www.artivabio.com/llms.txt","llms_full_txt":null,"last_checked":"2026-10-23T22:33:35.905Z","agent_terms":null,"categories":["healthcare","science-research"],"capabilities":[],"inferred_tags":["nk cell therapy","autoimmune disease","b-cell depletion","rheumatoid arthritis","clinical pipeline"],"audience":"business","agent_uses":["read_docs"],"language":"en","platform_generated":false,"agent_summary":"Artiva Biotherapeutics develops AlloNK, an investigational off-the-shelf NK cell therapy for B-cell depletion in autoimmune disease, entering Phase 3 in RA.","llms_txt_cached":"https://agentwebmap.com/v1/domain/artivabio.com/llms.txt","agentic":"documentation","section_keys":["categories","optional","pages","posts","team"],"section_partial":false,"section_indexed_at":"2026-10-21T14:25:49.777Z"}